% | $
Quotes you view appear here for quick access.

Onconova Therapeutics, Inc. Message Board

  • z_for_three z_for_three Feb 19, 2014 7:26 PM Flag

    More targeted Phase 3 trial will show strong results

    What's funny is how so much is riding on meeting the primary endpoint, when one really has to understand medicine today and where clinical trials are going. The goal of any drug is to give the right drug to the right patient, and the increasing focus on clinical protocol today, as the FDA supports, is more targeted patient populations. Now, ONTX's management has a VERY CLEAR patient population for Rigosertib...the ad-hoc, post analysis sub-population. Those are the patients which showed a statistically significant doubling of life expectancy, which is highly meaningful. This sub-population was a large portion of the trial, which is meaningful too. Going forward, I am highly confident that management will work with the FDA to develop a Phase 3 trial to target this sub-population in a multi-center, placebo control trial. And, the results, should be powerful. Expect a trial to start in early 2015, as the remainder of the year is spent analyzing this data, meeting with the FDA to set up the Phase 3 protocol and then enrolling patients.

    Ultimately,Rigosertib will double the lives of those patients who should be receiving the drug in the first place...and that is everyone's goal.

    Will add more on weakness.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.41+0.05(+2.12%)Mar 31 4:00 PMEDT